Investment case
Johnson & Johnson
JNJ · 71 developments mapped · last assessed 2026-09-26
Market Ontology has mapped 71 macro, policy, and market developments to Johnson & Johnson since 2026-08-11. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for JNJ yet, so no modelled value is shown. The JNJ valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run JNJ on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Citadel increases AbbVie stake over 500% amid institutional yield rotation
Second-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation.
· Moves cost of equity (ke) due to lower perceived risk and higher demand, market multiple expansion
- Main threat
10-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums
Increased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends.
· Moves equity risk premium, cost of capital
- Open question
Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
Similar to Pfizer, J&J has a broad pharmaceutical presence and could benefit from new opportunities but also face increased competition.
· Moves probability of success pipeline, addressable market size, competitive landscape
What changed, by assumption
- 2026-09-1810-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums
- 2026-09-15Citadel increases AbbVie stake over 500% amid institutional yield rotation
- 2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive Rotation
- 2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive Rotation
- 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-12 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
| 2026-07-15 | Revenue | Bullish | Company raised 2026 guidance to $101.1 Billion midpoint based on strong operational performance. | 1.00 |
| 2026-07-15 | Revenue | Bullish | Company raised 2026 sales guidance to $101.1 Billion at the midpoint. | 1.00 |
| 2026-07-15 | Revenue | Bullish | Company raised 2026 guidance with estimated reported sales of $101.1 Billion. | 1.00 |
| 2026-07-15 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-07-15 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-07-15 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
| 2026-07-15 | Margin | Bullish | Company increased adjusted EPS guidance by $0.13 to $11.68. | 0.95 |
| 2026-07-15 | Revenue | Bullish | Company raised 2026 guidance to estimated reported sales of $101.1 Billion. | 1.00 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | watch | 3-12m | 0.20 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | watch | 3-12m | 0.20 |
| 2026-09-24 | Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder | watch | 3-12m | 0.10 |
| 2026-09-24 | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026 | watch | 3-12m | 0.20 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Bearish | 3-12m | 0.30 |
| 2026-09-21 | Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD | watch | 1-5y | 0.20 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix | mixed | 3-12m | 0.10 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth | mixed | 1-3m | 0.30 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60% | watch | 3-12m | 0.20 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2 | mixed | 3-12m | 0.40 |
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Bearish | 1-3m | 0.40 |
| 2026-09-19 | Teva presents real-world data showing UZEDY treatment continuity advantage | watch | 3-12m | 0.20 |